Cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion: A case report emphasizing early detection

J Cutan Pathol. 2023 Dec;50(12):1059-1064. doi: 10.1111/cup.14526. Epub 2023 Sep 5.

Abstract

Rhabdomyosarcoma with TFCP2 rearrangement is a recently identified malignant neoplasm characterized by immunohistochemical evidence of rhabdomyoblastic differentiation, keratin expression, upregulation of ALK, and an aggressive clinical course. This neoplasm has a tendency to affect craniofacial bones, with only a few reported cases of extra-osseous tumors. Here, we present a case of cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion in a 35-year-old female. Notably, the tumor exhibited a pathologic spectrum, initially resembling sclerosing dermatitis at presentation but progressing into a high-grade malignant tumor within 8 months. The distinctive immunoprofile of this neoplasm highlights the importance of early molecular studies for diagnosis, even in the presence of low-grade cytomorphology. Early detection may offer an opportunity for timely resection before the tumor becomes unresectable.

Keywords: FUS-TFCP2; TCFP2; cutaneous rhabdomyosarcoma; epithelioid and spindle cell rhabdomyosarcoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Biomarkers, Tumor / genetics
  • Bone Neoplasms*
  • DNA-Binding Proteins
  • Early Detection of Cancer
  • Female
  • Humans
  • RNA-Binding Protein FUS / metabolism
  • Rhabdomyosarcoma* / chemistry
  • Rhabdomyosarcoma* / diagnosis
  • Rhabdomyosarcoma* / genetics
  • Transcription Factors / metabolism

Substances

  • Transcription Factors
  • Biomarkers, Tumor
  • TFCP2 protein, human
  • DNA-Binding Proteins
  • FUS protein, human
  • RNA-Binding Protein FUS